1. Adjuvant carboplatin intensified chemotherapy was superior to standard chemotherapy in improving survival outcomes in patients with high-risk, early-stage, triple-negative ...
1. BrECADD resulted in significantly lower treatment-related morbidity than eBEACOPP. 2. Progression-free survival at 48 months was significantly greater in ...
Click here to read this study in the NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Click here to read this study in Lancet Oncology. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. In this randomized controlled trial, cyclophosphamide-tacrolimus-mycophenolate mofetil was associated with lower rates of graft-versus-host disease (GVHD) compared to tacrolimus-methotrexate ...
1. The United States regimen had greater event-free survival and less associated febrile neutropenia compared to the European regimen. 2. ...
Click to read this study in the Journal of Clinical Oncology.
Click to read this study in JAMA Oncology.
